Gainesville, VA, United States of America

Aurelia Meloni-Ehrig

This inventor holds 12 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 3 EPO patents. Top assignee: Quest Diagnostics Investments, Inc.. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Aurelia Meloni-Ehrig. Retrieved from https://idiyas.com/inventor/aurelia-meloni-ehrig

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 3.0

ph-index = 4

Forward Citations = 50(Granted Patents)

Company Filing History:

12 out of 499

Quest Diagnostics Investments, Inc.

patents

Years Active: 2013-2025

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12305241 - EML4-ALK translocations in lung cancer (2025-05-20),

2. 11639529 - EML4-ALK translocations in lung cancer (2023-05-02),

3. 11021758 - Methods for detecting gene dysregulation by intragenic differential expression (2021-06-01),

4. 10501809 - Methods for detecting gene dysregulation by intragenic differential expression (2019-12-10),

5. 10435758 - EML4-ALK translocations in lung cancer (2019-10-08),

6. 10093985 - Methods for detecting gene dysregulation by intragenic differential expression (2018-10-09),

7. 9957573 - EML4-ALK translocations in lung cancer (2018-05-01),

8. 9546404 - Methods for detecting gene dysregulation by intragenic differential expression (2017-01-17),

9. 9187788 - Methods for detecting gene dysregulation by intragenic differential expression (2015-11-17),

10. 9175350 - EML4-ALK translocations in lung cancer (2015-11-03),

11. 8815516 - Methods for detecting gene dysregulation by intragenic differential expression (2014-08-26),

12. 8426133 - Methods for detecting gene dysregulation by intragenic differential expression (2013-04-23),

Title: Aurelia Meloni-Ehrig: Pioneering Innovator in Lung Cancer Diagnostics

Introduction

Aurelia Meloni-Ehrig is a distinguished inventor based in Gainesville, Virginia, who has made significant contributions to the field of medical diagnostics. With an impressive portfolio of 12 patents, her work primarily focuses on the diagnosis and evaluation of neoplastic disorders, particularly non-small cell lung cancer.

Latest Patents

Among her latest patents, Aurelia's research on EML4-ALK translocations in lung cancer stands out. This patent disclosure details advanced methods for diagnosing neoplastic disorders. Specifically, it describes assays that analyze patient test samples for the presence of specific EML4-ALK fusion genes associated with these disorders. The innovative approaches provided by her patents contribute to the improved detection and understanding of lung cancer.

Career Highlights

Aurelia Meloni-Ehrig is currently associated with Quest Diagnostics Investments, Inc., where she applies her expertise to enhance diagnostic practices. Her dedication to research and development in oncology has garnered recognition within the medical and scientific community, leading to advancements in more effective lung cancer diagnoses.

Collaborations

Throughout her career, Aurelia has worked alongside notable colleagues such as Maher Albitar and Heather R. Sanders. Collaborating with such esteemed professionals highlights her commitment to fostering innovation and excellence in medical research.

Conclusion

Aurelia Meloni-Ehrig's contributions to the field of lung cancer diagnostics exemplify the impact of innovative thinking in medicine. With 12 patents to her name and a continued focus on enhancing diagnostic methodologies, she remains a pivotal figure in the fight against neoplastic disorders. Her work not only aids in the early detection of cancer but also inspires future innovations in the field.

Profile summary based on public USPTO records.